low-risk
Showing 26 - 50 of >10,000
Pulmonary Embolism Trial in New York (FlowTriever)
Recruiting
- Pulmonary Embolism
- FlowTriever
-
New York, New YorkLenox Hill Hospital
Sep 22, 2022
Basal Cell Carcinoma, Elderly Trial in Ghent (Standard of care, Monitoring)
Recruiting
- Basal Cell Carcinoma
- Elderly
- Standard of care
- Monitoring
-
Ghent, East Flanders, BelgiumDepartment of Dermatology, Ghent University Hospital
Dec 5, 2022
Nasopharyngeal Carcinoma Trial in Guangzhou, Zhongshan, Nanning (IMRT and concurrent cisplatin, gemcitabine and cisplatin
Not yet recruiting
- Nasopharyngeal Carcinoma
- IMRT and concurrent cisplatin
- gemcitabine and cisplatin (Induction chemotherapy)
-
Guangzhou, Guangdong, China
- +3 more
Jul 30, 2023
Gestational Diabetes in Pregnancy Trial in Toronto (New Care Pathway)
Recruiting
- Gestational Diabetes Mellitus in Pregnancy
- New Care Pathway
-
Toronto, Ontario, CanadaSt. Michael's Hospital (Unity Health Toronto)
Oct 24, 2022
Identify Genes/Pathways Responsible for Progression From Low
Recruiting
- Prostate Cancer Stage I
-
Taipei, TaiwanNational Taiwan University
Aug 11, 2022
Breast Cancer, Radiotherapy Side Effect Trial in Beijing (Ultra-fractionated radiation therapy)
Recruiting
- Breast Cancer
- Radiotherapy Side Effect
- Ultra-fractionated radiation therapy
-
Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Mar 9, 2023
Breast Cancer Trial in Madison (REASSURE)
Recruiting
- Breast Cancer
- REASSURE
-
Madison, WisconsinUW Health Oncology Clinics
Dec 6, 2022
Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R Trial in Canada, United States (Etavopivat)
Recruiting
- Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
-
Ocala, Florida
- +3 more
Jan 30, 2023
Localized Prostate Cancer, Low Risk Prostate Cancer, Intermediate Risk Prostate Cancer Trial (3 fractions of prostate SBRT)
Not yet recruiting
- Localized Prostate Cancer
- +2 more
- 3 fractions of prostate SBRT
- (no location specified)
Oct 31, 2023
HER2-positive Breast Cancer Trial (Standard of Care Adjuvant Breast Radiation, Standard of Care HER2-targeted Therapy Without
Not yet recruiting
- HER2-positive Breast Cancer
- Standard of Care Adjuvant Breast Radiation
- Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation
- (no location specified)
Jan 20, 2023
Prostate Cancer Stage I, Bladder Outlet Obstruction Trial in Mansoura (Anatomical Endoscpic enucleation of the Prostate)
Active, not recruiting
- Prostate Cancer Stage I
- Bladder Outlet Obstruction
- Anatomical Endoscpic enucleation of the Prostate
-
Mansoura, DK, EgyptUrology and nephrology center
Nov 19, 2022
Low-risk Papillary Thyroid Cancer, Endocrine Malignancy, Thyroid Cancer Trial run by the NCI (Total Thyroidectomy (TT),
Terminated
- Low-risk Papillary Thyroid Cancer
- +2 more
- Total Thyroidectomy (TT)
- Prophylactic central neck lymph node dissection (pCND)
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 8, 2022
Diffuse Large B-cell Lymphoma Trial in Shanghai (Rituximab, Cyclophosphamide, Epirubicin)
Active, not recruiting
- Diffuse Large B-cell Lymphoma
- Rituximab
- +4 more
-
Shanghai, Shanghai, ChinaShanghai Ruijin Hospital
Dec 1, 2022
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma
Not yet recruiting
- Anatomic Stage 0 Breast Cancer AJCC v8
- +3 more
- Accelerated Partial Breast Irradiation
-
Duarte, CaliforniaCity of Hope Medical Center
Aug 18, 2023
Prostate Cancer Trial in Pittsburgh (Focal prostate brachytherapy with Cesium-131)
Withdrawn
- Prostate Cancer
- Focal prostate brachytherapy with Cesium-131
-
Pittsburgh, PennsylvaniaUPMC Mercy
Aug 23, 2022
MDS Trial (Fasting-mimicking diet (FMD) and physiotherapy)
Not yet recruiting
- Myelodysplastic Syndromes
- Fasting-mimicking diet (FMD) and physiotherapy
- (no location specified)
Jun 22, 2022
Breast Tumors Trial in Saint Louis (accelerated partial breast irradiation)
Active, not recruiting
- Breast Neoplasms
- accelerated partial breast irradiation
-
Saint Louis, MissouriWashington University School of Medicine
Nov 14, 2022
Pregnancy; Mental Disorders, COVID-19 Pandemic, Prenatal Stress Trial in Porto Alegre (Telemedicine appointment, Face-to-face
Not yet recruiting
- Pregnancy; Mental Disorders
- +2 more
- Telemedicine appointment
- Face-to-face appointment
-
Porto Alegre, Rio Grande Do Sul, BrazilIrmandade da Santa Casa de Misericórdia de Porto Alegre (ISCMPA)
Feb 23, 2023
Rectal Cancer Trial in China (neoadjuvant chemo plus total mesorectal excision, total mesorectal excision)
Recruiting
- Rectal Cancer
- neoadjuvant chemotherapy plus total mesorectal excision
- total mesorectal excision
-
Chongqing, Chongqing, China
- +5 more
Aug 8, 2023
Second-trimester Uterine Artery Doppler Analysis in Prediction
Completed
- Gestational Diabetes
- uterine artery doppler at 18-23 weeks of pregnancy
-
İstanbul, TurkeyHaseki Training and Research Hospital
Aug 2, 2022
BCC - Basal Cell Carcinoma, BCC, Excision Margin Trial in United States (CellFX System)
Completed
- BCC - Basal Cell Carcinoma
- +2 more
- CellFX System
-
Vestavia Hills, Alabama
- +4 more
Dec 15, 2022
COVID 19 Disease, Mild to Moderate COVID 19 Disease, SARS-CoV-2 Trial (Tafenoquine Oral Tablet, Placebo)
Not yet recruiting
- COVID 19 Disease
- +4 more
- Tafenoquine Oral Tablet
- Placebo
- (no location specified)
Jul 13, 2023
Human Immunodeficiency Virus Trial in Cleveland, Milwaukee (Social Network, Brief HIV Prevention Counseling)
Active, not recruiting
- Human Immunodeficiency Virus
- Social Network
- Brief HIV Prevention Counseling
-
Cleveland, Ohio
- +1 more
Aug 1, 2022
Acute Pulmonary Embolism, Outpatient Treatment Trial in Spain (Outpatient treatment with standard anticoagulant therapy)
Recruiting
- Acute Pulmonary Embolism
- Outpatient Treatment
- Outpatient treatment with standard anticoagulant therapy
-
Barcelona, Spain
- +9 more
May 9, 2023
Breast Cancer Trial in Limoges, Villejuif (Anti-aromatase inhibitor)
Not yet recruiting
- Breast Cancer
- Anti-aromatase inhibitor
-
Limoges, France
- +1 more
Jul 25, 2022